Mark J. Levis

Mark J. Levis

Oncology
401 North Broadway Street, Weinberg BLDG
Weinberg BLDG
Baltimore, MD 21287

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 213 publications

FLT3-ITD MRD is here to stay.

FLT3-ITD MRD is here to stay.

Journal: Blood advances
Published: August 14, 2026

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

QuANTUM-Wild: a Phase III, randomized trial of quizartinib in newly diagnosed FLT3-ITD-negative acute myeloid leukemia.

Journal: Future oncology (London, England)
Published: July 11, 2026

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: April 14, 2026

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Erratum to: "Impact of hematopoietic cell transplantation and quizartinib in newly diagnosed patients with acute myeloid leukemia and FMS-like tyrosine kinase 3-internal tandem duplications in the QuANTUM-First trial".

Journal: Haematologica
Published: April 01, 2026

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Regional practice differences significantly impact benefit from post-HCT gilteritinib for FLT3-ITD AML.

Journal: Blood advances
Published: March 25, 2026

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

A plasma-based DNA test for quantification of disease burden in acute myeloid leukemia patients undergoing bone marrow transplantation.

Journal: medRxiv : the preprint server for health sciences
Published: February 23, 2026

Timing of response in patients with relapsed/refractory FLT3 mut+ acute myeloid leukemia treated with gilteritinib.

Timing of response in patients with relapsed/refractory FLT3 mut+ acute myeloid leukemia treated with gilteritinib.

Journal: Blood neoplasia
Published: February 19, 2026

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Chemotherapy regimens with second generation tyrosine kinase inhibitors for BCR-ABL B-cell acute lymphoblastic leukemia: comparative outcomes and role of allogeneic hematopoietic cell transplantation.

Journal: Leukemia & lymphoma
Published: February 15, 2026

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Evolution to complex karyotype disease in mono-allelic TP53-mutated myelodysplastic syndrome/acute myeloid leukemia: a cohort study.

Journal: Haematologica
Published: February 15, 2026

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

ELN-DAVID recommendations for NGS-based FLT3-ITD MRD testing for patients with acute myeloid leukemia.

Journal: Blood
Published: February 04, 2026

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

ELN-DAVID Recommendations for NGS-based FLT3-ITD MRD Testing in Patients with Acute Myeloid Leukemia.

Journal: Blood
Published: February 04, 2026

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

A PBD-dimer containing antibody drug conjugate targeting CCRL2 for high-risk MDS/AML including TP53-mutated disease.

Journal: Blood advances
Published: December 11, 2025
Showing 1-12 of 213

Last Updated: 09/26/2026